Philippe Lopes-Fernandes, Ipsen CBO

Ex­clu­sive: A year in­to his role, Ipsen's CBO is on a $3B mis­sion to get the com­pa­ny 'back on the right track'

As a bio­phar­ma ex­ec, Philippe Lopes-Fer­nan­des had fol­lowed Ipsen’s $1.3 bil­lion buy­out of Clemen­tia and what then-CEO David Meek called a “large­ly de­risked” rare dis­ease pro­gram.

He al­so watched the en­su­ing set­backs that led to some se­ri­ous de­lays in the com­pa­ny’s time­line, Meek’s res­ig­na­tion, and a scrapped in­di­ca­tion. So when the com­pa­ny reached out ear­ly last sum­mer to see if Lopes-Fer­nan­des was in­ter­est­ed in the open chief busi­ness of­fi­cer po­si­tion, he thought it would be a “nice chal­lenge.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.